Patents by Inventor Xiaoqing Qiu

Xiaoqing Qiu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10962354
    Abstract: The invention relates to a selection method of loss control materials for lost circulation control in fractured reservoirs based on photoelastic experiments. By using the photoelastic material to simulate rigid lost circulation material, obtaining photoelastic images and load curves during a loading process of plugging zones formed by the lost circulation material, selecting the lost circulation material according to structure stability of plugging zones.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: March 30, 2021
    Assignee: Southwest Petroleum University
    Inventors: Chengyuan Xu, Xiaopeng Yan, Yili Kang, Hao Zhang, Haoran Jing, Jingyi Zhang, Chong Lin, Lijun You, Xiaoqing Qiu
  • Patent number: 10071358
    Abstract: Provided are a novel antibiotic preparation method and platform system based on the method, belonging to a novel drug development method. The method is based on a fixed structural formula: F—R, wherein F is an effect area, and R is an identification area. At the prior art level, the present invention can quickly develop a specific novel antibiotic for most pathogenic microorganisms or biological cells. Also provided is a platform for implementing the method, ensuring that the novel antibiotic is developed in an efficient streamlined process.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: September 11, 2018
    Assignee: PROTEIN DESIGN LAB, LTD.
    Inventor: Xiaoqing Qiu
  • Patent number: 9765378
    Abstract: The invention provides a method of preparing a new recombinant antibacterial polypeptide medicine, which primarily relates to liquid culture medium formula suitable for large-scale production of the antibacterial polypeptide, as well as optimization of the enlarged culture parameters.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: September 19, 2017
    Assignee: Creative Trio Biotech (Beijing) Co., Ltd.
    Inventors: Xiaoqing Qiu, Rongqi Li, Xiangli Zhang, Xiaofeng Zhang
  • Patent number: 9611299
    Abstract: Provided are methods for highly expressing recombinant protein of engineering bacteria and the use thereof. The method comprises the following steps: (1) engineering bacteria of Escherichia coli with pET system are transfected with recombinant mutated plasmid to obtain positive monoclonal colonies; (2) the positive monoclonal colonies are enriched to obtain a seed bacteria solution, and the seed bacteria solution is induced to enrichment and growth in a large amount; and (3) the bacteria supernatant containing the recombinant protein as the expression target is separated, and then the recombinant protein in the bacteria supernatant is extracted and purified. The method is characterized in that the engineering bacteria of Escherichia coli with pET system are E. coli B834 (DE3).
    Type: Grant
    Filed: November 23, 2012
    Date of Patent: April 4, 2017
    Assignee: Protein Design Lab, Ltd.
    Inventor: Xiaoqing Qiu
  • Patent number: 9572347
    Abstract: An agent for virus inactivation capable of exhibiting inactivation action based on structural destruction such as degradation and decomposition against viruses, which comprises a monovalent copper compound such as cuprous oxide, cuprous sulfide, cuprous iodide, and cuprous chloride as an active ingredient, and a virus inactivation material, which contains the agent for virus inactivation on a surface of a substrate and/or inside of the substrate.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: February 21, 2017
    Assignees: THE UNIVERSITY OF TOKYO, KANAGAWA ACADEMY OF SCIENCE AND TECHNOLOGY
    Inventors: Kazuhito Hashimoto, Kayano Sunada, Masahiro Miyauchi, Xiaoqing Qiu, Yoshinobu Kubota, Hitoshi Ishiguro, Ryuichi Nakano, Jitsuo Kajioka, Yanyan Yao
  • Publication number: 20160304927
    Abstract: The invention provides a method of preparing a new recombinant antibacterial polypeptide medicine, which primarily relates to liquid culture medium formula suitable for large-scale production of the antibacterial polypeptide, as well as optimization of the enlarged culture parameters.
    Type: Application
    Filed: March 1, 2012
    Publication date: October 20, 2016
    Applicant: BEIJING CREATED TRIBIOTECHNOLOGY CO., LTD.
    Inventors: Xiaoqing QIU, Rongqi LI, Xiangli ZHANG, Xiaofeng ZHANG
  • Patent number: 9359429
    Abstract: Provided are a hybridoma cell CGMCC No. 4783 that secretes a monoclonal antibody of an anti-cyanobacteria cell surface antigen, and the secreted monoclonal antibody thereof. Also provided are an anti-cyanobacteria recombinant antibody polypeptide, encoding gene, preparation method and use thereof. The anti-cyanobacteria recombinant antibody polypeptide is composed of an anti-cyanobacteria antibody mimetic polypeptide operably linearly connecting to the carboxyl terminal of an Escherichia coli polypeptide. The anti-cyanobacteria antibody mimetic polypeptide is a polypeptide with cyanobacteria identifying and binding capability designed based on an antigen binding fragment of the monoclonal antibody secreted by the CGMCC No. 4783 hybridoma cell. The anti-cyanobacteria recombinant antibody polypeptide directly form an ion channel on the cell membrane of a cyanobacteria to kill the cyanobacteria, targeted killing the cyanobacteria (prokaryote) without killing other beneficial eukaryotic cell algae.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: June 7, 2016
    Assignee: Protein Design Lab, Ltd.
    Inventor: Xiaoqing Qiu
  • Patent number: 9248432
    Abstract: A copper compound-carried titanium oxide photocatalyst which is excellent in a photocatalytic activity and a viral inactivation property and a production process for the same can be provided by a copper compound-carried titanium oxide photocatalyst comprising titanium oxide in which a content of rutile type titanium oxide is 50% by mole or more and a monovalent copper compound and a divalent copper compound which are carried on a surface of the titanium oxide described above and a production process for a copper compound-carried titanium oxide photocatalyst, comprising a step of carrying a monovalent copper compound and a divalent copper compound on a surface of titanium oxide in which a content of rutile type titanium oxide is 50% by mole or more.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: February 2, 2016
    Assignees: THE UNIVERSITY OF TOKYO, SHOW A DENKO K.K.
    Inventors: Kazuhito Hashimoto, Masahiro Miyauchi, Xiaoqing Qiu, Kayano Sunada, Yasushi Kuroda, Yasuhiro Hosogi, Ding Li, Yoshiki Shimodaira
  • Patent number: 9073989
    Abstract: The present invention belongs to field of biology and medicine, and especially relates to a novel antibiotic comprising an antibody mimetic antibody, its preparation methods and uses thereof. A novel antibiotic comprising a antibody mimetic covalently bonded to the carboxyl end of a colicin polypeptide or a channel-forming domain polypeptide of a colicin, wherein said colicin is selected from the group consisting of Colicin E1, Ia, Ib, A, B, N; wherein said antibody mimetic being yielded by fusing two complementarity determining regions (CDRs), VHCDR1 and VLCDR3 through a cognate framework region (VHFR2) of an immunoglobulin; wherein said the immunoglobulin specifically recognizes the bacterial porins. Its antibacterial ability is a thousandfold powerful than normal antibiotics. Due to its unique action mechanism, drug resistance resulted in mutation can hardly be acquired by pathogenic bacteria. And the antibiotic will not hurt normal human cells when it kills pathogenic bacteria.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: July 7, 2015
    Assignee: PROTEIN DESIGN LAB, LTD
    Inventor: Xiaoqing Qiu
  • Publication number: 20140349880
    Abstract: Provided are a novel antibiotic preparation method and platform system based on the method, belonging to a novel drug development method. The method is based on a fixed structural formula: F—R, wherein F is an effect area, and R is an identification area. At the prior art level, the present invention can quickly develop a specific novel antibiotic for most pathogenic microorganisms or biological cells. Also provided is a platform for implementing the method, ensuring that the novel antibiotic is developed in an efficient streamlined process.
    Type: Application
    Filed: December 10, 2012
    Publication date: November 27, 2014
    Applicant: PROTEIN DESIGN LAB, LTD.
    Inventor: Xiaoqing Qiu
  • Patent number: 8883161
    Abstract: The present invention provides a fusion polypeptide against EB virus-induced tumor, which comprises an antibody or a mimetic antibody against EB virus and an ion channel forming colicin selected form E1, Ia, Ib, A, B, N and their mutants. The present invention also provides a colicin Ia mutant, which comprises mutations of G11A, H22G, A26G, V31L, and H40D. The present invention also provides a gene, vector, preparation method and use of the fusion polypeptide, and provides a gene and use of the mutant.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: November 11, 2014
    Assignee: Protein Design Lab, Ltd.
    Inventor: Xiaoqing Qiu
  • Publication number: 20140322754
    Abstract: Provided are methods for highly expressing recombinant protein of engineering bacteria and the use thereof. The method comprises the following steps: (1) engineering bacteria of Escherichia coli with pET system are transfected with recombinant mutated plasmid to obtain positive monoclonal colonies; (2) the positive monoclonal colonies are enriched to obtain a seed bacteria solution, and the seed bacteria solution is induced to enrichment and growth in a large amount; and (3) the bacteria supernatant containing the recombinant protein as the expression target is separated, and then the recombinant protein in the bacteria supernatant is extracted and purified. The method is characterized in that the engineering bacteria of Escherichia coli with pET system are E. coli B834 (DE3).
    Type: Application
    Filed: November 23, 2012
    Publication date: October 30, 2014
    Inventor: Xiaoqing Qiu
  • Publication number: 20140170170
    Abstract: Provided are a hybridoma cell CGMCC No. 4783 that secretes a monoclonal antibody of an anti-cyanobacteria cell surface antigen, and the secreted monoclonal antibody thereof. Also provided are an anti-cyanobacteria recombinant antibody poly-peptide, encoding gene, preparation method and use thereof. The anti-cyanobacteria recombinant antibody polypeptide is composed of an anti-cyanobacteria antibody mimetic polypeptide operably linearly connecting to the carboxyl terminal of an Escherichia coli polypeptide. The anti-cyanobacteria antibody mimetic polypeptide is a polypeptide with cyanobacteria identifying and binding cap-ability designed based on an antigen binding fragment of the monoclonal antibody secreted by the CGMCC No.4783 hybridoma cell. The anti-cyanobacteria recombinant antibody polypeptide directly form an ion channel on the cell membrane of a cyanobacteria to kill the cyanobacteria, targeted killing the cyanobacteria (prokaryote) without killing other beneficial eukaryotic cell algae.
    Type: Application
    Filed: March 27, 2012
    Publication date: June 19, 2014
    Applicant: Protein Design Lab,Ltd
    Inventor: Xiaoqing Qiu
  • Publication number: 20130344124
    Abstract: An agent for virus inactivation capable of exhibiting inactivation action based on structural destruction such as degradation and decomposition against viruses, which comprises a monovalent copper compound such as cuprous oxide, cuprous sulfide, cuprous iodide, and cuprous chloride as an active ingredient, and a virus inactivation material, which contains the agent for virus inactivation on a surface of a substrate and/or inside of the substrate.
    Type: Application
    Filed: December 22, 2010
    Publication date: December 26, 2013
    Applicants: KANAGAWA ACADEMY OF SCIENCE AND TECHNOLOGY, THE UNIVERSITY OF TOKYO
    Inventors: Kazuhito Hashimoto, Kayano Sunada, Masahiro Miyauchi, Xiaoqing Qiu, Yoshinobu Kubota, Hitoshi Ishiguro, Ryuichi Nakano, Jitsuo Kajioka, Yanyan Yao
  • Publication number: 20130281283
    Abstract: A copper compound-carried titanium oxide photocatalyst which is excellent in a photocatalytic activity and a viral inactivation property and a production process for the same can be provided by a copper compound-carried titanium oxide photocatalyst comprising titanium oxide in which a content of rutile type titanium oxide is 50% by mole or more and a monovalent copper compound and a divalent copper compound which are carried on a surface of the titanium oxide described above and a production process for a copper compound-carried titanium oxide photocatalyst, comprising a step of carrying a monovalent copper compound and a divalent copper compound on a surface of titanium oxide in which a content of rutile type titanium oxide is 50% by mole or more.
    Type: Application
    Filed: June 22, 2012
    Publication date: October 24, 2013
    Applicants: THE UNIVERSTIY OF TOKYO, SHOWA DENKO K.K.
    Inventors: Kazuhito Hashimoto, Masahiro Miyauchi, Xiaoqing Qiu, Kayano Sunada, Yasushi Kuroda, Yasuhiro Hosogi, Ding Li, Yoshiki Shimodaira
  • Patent number: 8563503
    Abstract: The present invention belongs to field of biology and medicine, and especially relates to a novel antibiotic, its nucleotide sequence, methods of construction and uses thereof. A novel antibiotic, wherein the end of any peptide of the allosteric colicin is connected linearly to the end of peptide of the Staphylococcus aureus pheromone AgrD I, AgrD II, AgrD III, AgrD IV or Staphylococcus epidermidis pheromone. Wherein the allosteric colicin being yielded by artificially mutating the amino acid residues G11A, H22R, A26G, V31L and H40K in the peptide chain of wild type Colicin E1, Ia, Ib, A, B, N, or their ion channel-forming structural domain. In comparison with the traditional antibiotics, the novel antibiotics in the present invention are not likely to lead to drug resistance and cause hypersensitivity reaction.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: October 22, 2013
    Assignee: Protein Design Lab. Ltd.
    Inventor: Xiaoqing Qiu
  • Publication number: 20130066051
    Abstract: The present invention provides a fusion polypeptide against EB virus-induced tumor, which comprises an antibody or a mimetic antibody against EB virus and an ion channel forming colicin selected form E1, Ia, Ib, A, B, N and their mutants. The present invention also provides a colicin Ia mutant, which comprises mutations of G11A, H22G, A26G, V31L, and H40D. The present invention also provides a gene, vector, preparation method and use of the fusion polypeptide, and provides a gene and use of the mutant.
    Type: Application
    Filed: February 26, 2010
    Publication date: March 14, 2013
    Applicant: PROTEIN DESIGN LAB, LTD.
    Inventor: Xiaoqing Qiu
  • Publication number: 20120202734
    Abstract: The present invention belongs to field of biology and medicine, and especially relates to a novel antibiotic, its nucleotide sequence, methods of construction and uses thereof. A novel antibiotic, wherein the end of any peptide of the allosteric colicin is connected linearly to the end of peptide of the Staphylococcus aureus pheromone AgrD I, AgrD II, AgrD III, AgrD IV or Staphylococcus epidermidis pheromone. Wherein the allosteric colicin being yielded by artificially mutating the amino acid residues G11A, H22R, A26G, V31L and H40K in the peptide chain of wild type Colicin E1, Ia, Ib, A, B, N, or their ion channel-forming structural domain. In comparison with the traditional antibiotics, the novel antibiotics in the present invention are not likely to lead to drug resistance and cause hypersensitivity reaction.
    Type: Application
    Filed: February 7, 2011
    Publication date: August 9, 2012
    Applicant: PROTEIN DESIGN LAB, LTD.
    Inventor: Xiaoqing Qiu
  • Publication number: 20120190826
    Abstract: The present invention belongs to field of biology and medicine, and especially relates to a novel antibiotic comprising an antibody mimetic antibody, its preparation methods and uses thereof. A novel antibiotic comprising a antibody mimetic covalently bonded to the carboxyl end of a colicin polypeptide or a channel-forming domain polypeptide of a colicin, wherein said colicin is selected from the group consisting of Colicin E1, Ia, Ib, A, B, N; wherein said antibody mimetic being yielded by fusing two complementarity determining regions (CDRs), VHCDR1 and VLCDR3 through a cognate framework region (VHFR2) of an immunoglobulin; wherein said the immunoglobulin specifically recognizes the bacterial porins. Its antibacterial ability is a thousandfold powerful than normal antibiotics. Due to its unique action mechanism, drug resistance resulted in mutation can hardly be acquired by pathogenic bacteria. And the antibiotic will not hurt normal human cells when it kills pathogenic bacteria.
    Type: Application
    Filed: January 25, 2011
    Publication date: July 26, 2012
    Applicant: Protein Design Lab, Ltd.
    Inventor: Xiaoqing Qiu
  • Patent number: 6942993
    Abstract: Engineered antibiotic peptides and the preparation thereof are provided. The engineered antibiotic peptides, designated pheromonicins, are prepared by linking different bacteriocins or their functional domains with bacterial pheromones. Also provided are methods for treating bacterial infections by use of the antibiotic peptides.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: September 13, 2005
    Assignee: Sichuan NTC Holdings Limited
    Inventor: Xiaoqing Qiu